# US 2023/0047838 A1 · Modulation of lipid metabolism for protein production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0047838 A1
- Document ID: US20230047838A1
- Status: Published application
- Kind: A1
- Application number: 17/815,465
- Filed: 2022-07-27
- Published: 2023-02-16
- Earliest claimed: 2016-05-03
- Assignees: Lonza Ltd.
- Applicants: Lonza Ltd
- Inventors: James BUDGE; Christopher Mark SMALES; Tanya Jeane KNIGHT; Robert YOUNG
- Web page: https://patentgrep.com/patent/US20230047838A1

## CPC

- C12N 15/85: for animal cells
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 5/0682: {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609)}
- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12N 9/0083: {Miscellaneous (1.14.99)}
- C12N 9/0097: {acting on reduced flavodoxin as donor (1.19)}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12Y 114/19001: Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

The present disclosure features methods and compositions for modulating lipid metabolism to achieve improved production and quality of recombinant products, such as next generation biologics. Modulation of lipid metabolism as described herein includes, for example, introducing a lipid metabolism modulator described herein to a cell or a cell-free system. Also encompassed by the present disclosure are engineered cells with improved production capacity and improved product quality, methods for engineering such cells, and preparations and mixtures comprising the products from such cells.

## Claims

### Claim at position 1

1-44. (canceled)

### Claim 45

A method for producing a recombinant therapeutic polypeptide in a cell, the method comprising:
(i) providing a eukaryotic cell comprising a first exogenous nucleic acid encoding a first lipid metabolism modulator (LMM) comprising Sterol Regulatory Element-Binding Transcription Factor 1 (SREBF1), or a functional fragment or isoform thereof; and a second exogenous nucleic acid encoding the recombinant therapeutic polypeptide, wherein the recombinant therapeutic polypeptide is selected from an antibody, an antibody fragment, a hormone, a blood clotting factor, a cytokine or a protein vaccine; and
(ii) culturing the cell under conditions where the first LMM and the recombinant therapeutic polypeptide are expressed,
thereby producing the recombinant therapeutic polypeptide.

### Claim 46 (depends on 45)

The method of claim 45, wherein the first LMM provides an increased yield or rate of production of the recombinant therapeutic polypeptide as compared to a cell not having the first LMM.

### Claim 47 (depends on 46)

The method of claim 46, wherein the yield or rate of production of the recombinant therapeutic polypeptide is increased by 100% or more, as compared to the level or quantity of polypeptide produced by a cell without the first LMM.

### Claim 48 (depends on 45)

The method of claim 45, wherein the first LMM provides an increased ratio of properly folded recombinant therapeutic polypeptide to misfolded or unfolded recombinant therapeutic polypeptide as compared to a cell not having the first LMM.

### Claim 49 (depends on 45)

The method of claim 45, wherein the first LMM comprises an amino acid sequence with at least 80% identity with the amino acid sequence of SREBF1 corresponding to SEQ ID NOs: 1 or 34, or a functional fragment thereof corresponding to SEQ ID NOs: 26, 27, or 36; or differs by 1 or more amino acid residues but no more than 50 amino acid residues from the amino acid sequence of SREBF1, corresponding to SEQ ID NOs: 1 or 34, or a functional fragment thereof corresponding to SEQ ID NOs: 26, 27, or 36.

### Claim 50 (depends on 45)

The method of claim 45, wherein the cell further comprises a third exogenous nucleic acid encoding a second LMM comprising stearoyl CoA desaturase-1 (SCD1) or a functional fragment or isoform thereof, and in step (ii) the cell is cultured under conditions where the second LMM is expressed.

### Claim 51 (depends on 50)

The method of claim 50, wherein the second LMM comprises an amino acid sequence with at least 80% identity with the amino acid sequence of SEQ ID NO: 3, or a functional fragment thereof; or differs by 1 or more amino acid residues but no more than 50 amino acid residues from the amino acid sequence of SEQ ID NO: 3, or a functional fragment thereof.

### Claim 52 (depends on 45)

The method of claim 45, wherein the nucleic acid encoding the first LMM is integrated into the chromosomal genome of the cell and the LMM is stably expressed.

### Claim 53 (depends on 45)

The method of claim 45, wherein the cell is a mammalian cell.

### Claim 54 (depends on 53)

The method of claim 53, wherein the cell is a CHO cell.

### Claim 55 (depends on 45)

The method of claim 45, further comprising separating the recombinant therapeutic polypeptide from at least one cellular or medium component.

### Claim 56 (depends on 45)

The method of claim 45, wherein the second exogenous nucleic acid encoding a recombinant therapeutic polypeptide has been introduced after introducing the first exogenous nucleic acid encoding the first LMM.
